Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer

Full text
Monteiro, Hugo P. [1] ; Costa, Paulo E. [1] ; Reis, Adriana K. C. A. [2] ; Stern, Arnold [3]
Total Authors: 4
[1] Univ Fed Sao Paulo, Escola Paulista Med, Ctr Cellular & Mol Therapy CTCMol, Dept Biochem, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Dept Ciencias Exatase Terra, Sao Paulo, SP - Brazil
[3] NYU, Sch Med, Dept Biochem & Mol Pharmacol, 462 1st Ave, New York, NY 10016 - USA
Total Affiliations: 3
Document type: Review article
Source: BIOMEDICAL JOURNAL; v. 38, n. 5, p. 380-388, SEP-OCT 2015.
Web of Science Citations: 18

Cancer is a worldwide health problem leading to a high incidence of morbidity and mortality. Malignant transformation can occur by expression of oncogenes, over-expression and deregulated activation of proto-oncogenes, and inactivation of tumor suppressor genes. These cellular actions occur through stimulation of oncogenic signaling pathways. Nitric oxide (NO) can induce genetic changes in cells and its intracellular generation can lead to tumor formation and progression. It can also promote anti-tumor activities. The pro- and anti-tumor activities of NO are dependent on its intracellular concentration, cell compartmentalization, and cell sensitivity. NO affects a number of oncogenic signaling pathways. This review focuses on two oncogenic signaling pathways: NO-EGFR-Src-FAK and NO-Ras-EGFR-ERK1/2 MAP kinases. In these pathways, low to intermediate concentrations of NO/S-nitrosothiols (RSNOs) stimulate oncogenic signaling, while high concentrations of NO/RSNO stimulate anti-oncogenic signaling. Increasing knowledge on pro- and anti-tumorigenic activities of NO and related reactive species such as RSNOs has fostered the research and synthesis of novel NO-based chemotherapeutic agents. RSNOs, effective as NO donors and trans-nitrosylating agents under appropriate conditions, may operate as potential chemotherapeutic agents. (AU)

FAPESP's process: 12/10470-1 - A role for nitric oxide and for the inducible isoform of nitric oxide synthase in human colon cancer progression
Grantee:Hugo Pequeno Monteiro
Support type: Regular Research Grants
FAPESP's process: 10/19013-7 - Participation of nitric oxide and Src kinase in the estrogen-stimulated cell signaling pathway in human mammary tumor cells
Grantee:Hugo Pequeno Monteiro
Support type: Regular Research Grants
FAPESP's process: 13/16644-4 - S-nitrosothiols from Aryl-amide and Aryl-pyrimidin-2-ones (thiones) derivatives - potential double inhibitors of HIV-1-PR and renin: synthesis, structural analysis and biological tests
Grantee:Adriana Karla Cardoso Amorim Reis
Support type: Regular Research Grants